Management and characteristics of patients with metastatic prostate cancer in a cohort of New Zealand men

Oncology (Switzerland)

Volumn 88, Issue 3, 2015, Pages 157-163

  Lawrenson, Ross ^a   Lao, Chunhuan ^a   Obertová, Zuzana ^a   Brown, Charis ^a   Holmes, Michael ^a   Tyrie, Leanne ^a   Scott, Nina ^a   Fong, Peter ^a   Laking, George ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Androgen deprivation therapy; Castration resistant prostate cancer; Chemotherapy; Metastatic prostate cancer; Radiotherapy; Survival

Indexed keywords

BICALUTAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUTAMIDE; GOSERELIN; LEUPRORELIN; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); METASTATIC PROSTATE CANCER; NEW ZEALAND; PRIORITY JOURNAL; PROSTATE CANCER; VERY ELDERLY; ETHNOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM METASTASIS; PATHOLOGY; PROSTATIC NEOPLASMS; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEW ZEALAND; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84924255717     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000368319     Document Type: Article

References (23)

1. Ministry of Health: Cancer: New Registrations and Deaths 2010. Wellington, Ministry of Health, 2013.
2. Lawrenson R, Brown C, Obertova Z, Lao C, Conaglen H: Midlands Prostate Cancer Study: Final Report to the Ministry of Health. Unpublished.
3. Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906-910.
4. South West Public Health Observatory: SWPHO Briefing 4: Prostate Cancer Survival by Stage. 2008. http://www.swpho.nhs.uk/resource/view.aspx?RID=41287.
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
6. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98: 839-845.
7. Ministry of Health: Diagnosis and Management of Prostate Cancer in New Zealand Men. Wellington, Ministry of Health, 2012.
8. Lawrenson R, Obertová Z, Brown C, Fong P, Tyrie L, Scott N, Holmes M: The use of androgen deprivation therapy (ADT) and chemotherapeutic agents in New Zealand men with prostate cancer. J Cancer 2014; 5: 214-220.
9. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
10. Kirby M, Hirst C, Crawford ED: Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65: 1180-1192.
11. Cetin K, Beebe-Dimmer JL, Fryzek JP, Markus R, Carducci MA: Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology 2010; 75: 1396-1404.
12. Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A, Villavicencio H, Cantalapiedra A, Pedrosa E: Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010. BJU Int 2012; 110(11 Pt B):E701-E706.
13. Brasso K, Ingimarsdóttir IJ, Rusch E, Engholm G, Adolfsson J, Tryggvadóttir L, Jónsson E, Bill-Axelson A, Holmberg E, Storm HH: Differences in survival from prostate cancer in Denmark, Iceland and Sweden. Eur J Cancer 2013; 49: 1984-1992.
14. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD: Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer 2012; 118: 5947-5954.
15. NICE: Prostate cancer: diagnosis and treatment. NICE clinical guideline 175. 2014. http://www.nice.org.uk/guidance/cg175/chapter/recommendations.
16. Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, et al: Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999; 4:i-x, 1-246, I1-I36, passim.
17. Goethuys H, Baert L, Van Poppel H, Lieskovsky G, Brady LW, Petrovich Z: Treatment of metastatic carcinoma of the prostate. Am J Clin Oncol 1997; 20: 40-45.
18. Schröder FH, Whelan P, De Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, Van Velthoven RF, Debois M, Collette L: Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the 'European Organization for Research and Treatment of Cancer' (EORTC) protocol 30892. Eur Urol 2004; 45: 457-464.
19. Anderson J: The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-461.
20. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-577.
21. Iannazzo S, Pradelli L, Carsi M, Perachino M: Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value Health 2011; 14: 80-89.
22. Taplin ME: Secondary hormone therapy for castration-resistant prostate cancer. Oncology 2013; 27.pii:168979.
23. MacVicar GR, Hussain MH: Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol 2013; 25: 252-260.